Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic leukemia. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CD19/CD20 CAR-T cells (CD19/CD20 chimeric antigen receptor T cells)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: CD19 Positive, CD20 Positive | Phase 1 | Status: ACTIVE_NOT_RECRUITING